Benzinga
Benzinga
Notizie dall’Italia
Azioni
Indici
Obbligazioni
ETF
Economia
Generale
Notizie USA
Azioni
Indici
Utili
Notizie Economiche
Mercati di previsione
Mercati privati
Altri Mercati
Dicono gli Analisti
Trading
Comunicati stampa
Notizie internazionali
Europa
Asia
Criptovalute
Notizie
Altcoin
Bitcoin
Blockchain
Dogecoin
Ethereum
Shiba Inu
NFT
Finanza personale
Investire in criptovalute
Investire in azioni
Forex
Benzinga
martedì, ottobre 06
Notizie dall’Italia
Azioni
Indici
Obbligazioni
ETF
Economia
Generale
Notizie USA
Azioni
Indici
Utili
Notizie Economiche
Mercati di previsione
Mercati privati
Altri Mercati
Dicono gli Analisti
Trading
Comunicati stampa
Notizie internazionali
Europa
Asia
Criptovalute
Notizie
Altcoin
Bitcoin
Blockchain
Dogecoin
Ethereum
Shiba Inu
NFT
Finanza personale
Investire in criptovalute
Investire in azioni
Forex
BioLife Solutions Inc
BLFS
NASDAQ
Watchlist
Get Report
Trade with Public
Get Report
Trade with Public
$39.00
0.39
1.01%
Ult. Agg.: Oct 5, 4:15 PM
$39.00
0.39
1.01%
Get Report
Panoramica
Notizie
Previsioni utili
Eventi
Obiettivi di prezzo
Dati finanziari
Sentiment
Azionariato
Confronta
Opzioni
Rapporto azionario
Privacy Manager
Fusioni e acquisizioni:
BioLife Solutions (BLFS) was acquired by Repligen (RGEN) on Tuesday, October 6, 2026 for $1.5B paid in cash & stock
BioLife Solutions Financials
BioLife Solutions (BLFS) financial statements — income, revenue, gross margin and key metrics.
Earnings & Guidance News
PRO
BioLife Solns Q2 Sales $28.466M Beat $27.683M Estimate
Benzinga Newsdesk
PRO
BioLife Solutions Affirms FY2026 Sales Guidance of $112.500M-$115.000M vs $112.942M Est
Benzinga Newsdesk
PRO
BioLife Solns Q1 Adj. EPS $0.04 Beats $0.02 Estimate, Sales $27.500M Beat $25.664M Estimate
Benzinga Newsdesk
BioLife Solutions Earnings Report: Q4 Overview
Benzinga Insights
PRO
BioLife Solutions Sees FY2026 Sales $112.500M-$115.000M vs $111.058M Est.
BioLife Solutions (NASDAQ:BLFS) sees FY2026 sales of $112.500 million-$115.000 million vs $111.058 million analyst estimate.
Benzinga Newsdesk
PRO
BioLife Solns Q4 Adj. EPS $0.04 Beats $(0.02) Estimate, Sales $24.764M Beat $24.082M Estimate.
BioLife Solns (NASDAQ:BLFS) reported quarterly earnings of $0.04 per share which beat the analyst consensus estimate of $(0.02) by 281.82 percent. This is a 300 percent increase over losses of $(0.02) per share from the
Benzinga Newsdesk
